Nanoscope Therapeutics will present data from its geographic atrophy and retinitis pigmentosa programs at the 26th Euretina Congress (1-4 October 2026) and at the Retina Forum in the Ophthalmology Futures Forums on 30 September 2026, in Vienna.
Jordi Mones, MD, PhD, is scheduled to present the first direct-to-phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy for macular degeneration on 4 October 2026, and Benjamin Bakall, MD, PhD, will present four-year REMAIN extension study data on lasting vision improvement with MCO-010 in retinitis pigmentosa.
Samarendra Mohanty, PhD, will deliver a company presentation and Samuel Barone, MD, will participate in a panel on geographic atrophy and intermediate age-related macular degeneration.
The company states that its MOGENRY intravitreal optogenetic therapy has a biologics license application accepted and filed by the FDA following RESTORE phase 2b/3 results and that MCO-010 showed promising STARLIGHT phase 2 data with plans for a phase 3 registrational trial in 2026; the company also cites multiple regulatory designations for MCO-010.
MOGENRY does not require genetic testing, invasive surgery, or repeat dosing and is designed for administration within existing retina office workflows.
